Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network combines the experience of European clinicians and scientists working on these groups of diseases. Over the past year, they have assembled the largest collection of families and achieved a number of tasks (initiation of a clinical and genetic database, distribution of DNA to participating laboratories, mapping of three new loci, and refinement of several loci). In addition to clinicians from Europe and Mediterranean countries, who play a major role in collecting families according to evaluation tools developed and validated by the SPATAX members, the group includes major European laboratories devoted to the elucidation of the molecular basis of these disorders. Each laboratory will centralize all families with a subtype of autosomal recessive (AR) CA (n=116) or SP (n=207) in order to efficiently map and identify the responsible gene(s). Genome-wide scans are already underway in 61 families. Given the expertise of the participants, the researchers expect to map and identify several genes during the course of this project. The spectrum of mutations and phenotype/genotype correlations will be analysed thanks to this unique series of patients with various phenotypes. The knowledge gained will be immediately applicable to patients in terms of improved positive diagnosis, follow-up and appropriate genetic counselling. In the long term, models for genetic entity will be developed in order to understand the pathophysiology and to identify new targets for treatment. The series of patients assembled and the precise knowledge of natural history will facilitate the implantation of therapeutic trials based on rational approaches.
Study Type
OBSERVATIONAL
Enrollment
6,000
CHU Mustapha
Algiers, Algeria
Université Libre de Bruxelles - Hôpital Erasme
Brussels, Belgium
The Panum Institute
Copenhagen, Denmark
CHU d'Angers
Angers, France
Hôpital Pellegrin
Bordeaux, France
Hôpitaux de Clermont-Ferrand
Clermont-Ferrand, France
CHU
Grenoble, France
Hôpital de la Timone
Marseille, France
Hôpital Carémeau
Nîmes, France
Hôpital Armand Trousseau
Paris, France
...and 17 more locations
Characterize clinically the different forms of these diseases
Validation of a new quantitative tool with more sensitive grading scale of cerebellar syndrome, spasticity and their consequences. In one single device, three tests were assessed for hand coordination ( " tapping test ", " peg board test" and " click test "), one test for dysarthria and a final test to quantify walking disorders due to spasticity (distance covered in 5 seconds).
Time frame: Year 1 to Year 7
Elucidate the molecular bases of these diseases
To elucidate the molecular bases of these diseases (identify the loci/genes involved as well as those that modulate their expression) in order to enable the development of molecular diagnostics, the study of disease mechanisms, the identification of biomarkers and, subsequently, to propose new treatments.
Time frame: through study duration (through study duration (up to 14 years) )
Establish the natural history of spino-cerebellar degeneration
Investigators intended to follow the clinical status of this cohort of patients for 7 years, by assessing the progression of the pathology each year with a neurological exam
Time frame: Year 1 to Year 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.